Nonseminomatous Germ Cell Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NSGCT MCID: NNS011 MIFTS: 32	Nonseminomatous Germ Cell Tumor (NSGCT) Categories: Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Nonseminomatous Germ Cell Tumor

MalaCards integrated aliases for Nonseminomatous Germ Cell Tumor:

Name: Nonseminomatous Germ Cell Tumor ²⁰ ⁷⁰

Non-Seminomatous Germ-Cell Tumors ²⁰

Germ Cell Tumor, Nonseminomatous ⁶

Nsgct ²⁰

Classifications:

MalaCards categories:
Global: Rare diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷⁰ C1266158

Sources

Summaries for Nonseminomatous Germ Cell Tumor

GARD : ²⁰ Nonseminomatous germ cell tumors are cancerous tumors commonly found in the pineal gland in the brain, in the mediastinum, or in the abdomen. They originate from cells that were meant to form sex cells (i.e., sperm or eggs). They are often large and have a tendency to spread more quickly than the other type of germ cell tumor (i.e., seminoma type). Possible early signs of this cancer include chest pain and breathing problems.

MalaCards based summary : Nonseminomatous Germ Cell Tumor, also known as non-seminomatous germ-cell tumors, is related to testicular germ cell tumor and teratoma. An important gene associated with Nonseminomatous Germ Cell Tumor is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are MAPK Pathway and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Cisplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include testis, lymph node and pineal, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Nonseminomatous Germ Cell Tumor

Diseases related to Nonseminomatous Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)

#	Related Disease	Score	Top Affiliating Genes
1	testicular germ cell tumor	32.1	BRAF AFP
2	teratoma	31.0	CGB7 CGB5 AFP
3	endodermal sinus tumor	30.7	CGB5 AFP
4	malignant teratoma	30.6	CGB5 AFP
5	mature teratoma	30.5	ERBB2 BRAF AFP
6	trophoblastic neoplasm	30.4	CGB5 AFP
7	extragonadal germ cell cancer	30.4	CGB5 AFP
8	gonadal germ cell tumor	30.3	CGB5 AFP
9	choriocarcinoma	30.2	CGB7 CGB5
10	seminoma	30.1	CGB7 CGB5 AFP
11	placental site trophoblastic tumor	29.9	ERBB2 CGB5
12	gynecomastia	29.9	ERBB2 CGB5
13	extragonadal nonseminomatous germ cell tumor	11.5
14	germ cells tumors	11.2
15	testicular cancer	10.7
16	embryonal carcinoma	10.6
17	germ cell cancer	10.6
18	testicular germ cell cancer	10.5
19	growing teratoma syndrome	10.5
20	testicular yolk sac tumor	10.5
21	teratocarcinoma	10.4
22	mixed germ cell tumor	10.4
23	lymphocele	10.3
24	mucositis	10.2
25	hypogonadotropic hypogonadism	10.2
26	respiratory failure	10.2
27	adult respiratory distress syndrome	10.2
28	pancreatic adenocarcinoma	10.2
29	spermatocytoma	10.2
30	testicular spermatocytic seminoma	10.2
31	hyperthyroidism	10.2
32	renal cell carcinoma, nonpapillary	10.1
33	sarcoidosis 1	10.1
34	renal hypodysplasia/aplasia 1	10.1
35	ascites, chylous	10.1
36	chondrosarcoma	10.1
37	leukemia, acute myeloid	10.1
38	sarcoidosis 3	10.1
39	deficiency anemia	10.1
40	mastitis	10.1
41	hemopericardium	10.1
42	infant gynecomastia	10.1
43	pericardial effusion	10.1
44	thrombocytopenia	10.1
45	central nervous system disease	10.1
46	urinary tract obstruction	10.1
47	infertility	10.1
48	hemolytic anemia	10.1
49	severe combined immunodeficiency	10.1
50	nervous system disease	10.1

Graphical network of the top 20 diseases related to Nonseminomatous Germ Cell Tumor:

Sources

Symptoms & Phenotypes for Nonseminomatous Germ Cell Tumor

GenomeRNAi Phenotypes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

²⁶ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-134	9.47	CGB5 CGB7
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.47	BRAF
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.47	ERBB2
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.47	ERBB2
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	9.47	ERBB2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.47	CGB5 CGB7 ERBB2
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.47	BRAF
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.47	ERBB2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.47	ERBB2
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.47	ERBB2
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.47	ERBB2

Sources

Drugs & Therapeutics for Nonseminomatous Germ Cell Tumor

Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatin

Cisplatine

cisplatino

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Synonyms:

(+-)-Ifosfamid

(+-)-Ifosphamide

(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

(D,L)-Ifosfamide

(R,S)-Ifosphamide

(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3,} 2-oxazaphosphorine oxide

36341-88-5

3778-73-2

84711-20-6

A 4942

AB00513932

AC1L1GHW

AC-2113

Ambap3778-73-2

Asta Z 4942

ASTA Z 4942

BPBio1_000865

BRN 0611835

BSPBio_000785

C07047

CAS-3778-73-2

CCRIS 352

CHEBI:5864

CHEMBL1024

CID3690

Cyfos

D00343

D007069

DB01181

EINECS 223-237-3

HMS1570H07

HMS2090M12

HMS2093N07

Holoxan

Holoxan 1000

HSDB 7023

I06-0494

Ifex

IFEX (TN)

Ifosfamid

Ifosfamida

Ifosfamida [INN-Spanish]

ifosfamide

Ifosfamide

Ifosfamide (JAN/USP/INN)

Ifosfamide [USAN:INN:BAN:JAN]

Ifosfamide sterile

Ifosfamide Sterile

Ifosfamidum

Ifosfamidum [INN-Latin]

Ifosphamide

Ifsofamide

Iphosphamid

Iphosphamid(e)

Iphosphamide

I-phosphamide

I-Phosphamide

Iso endoxan

Iso Endoxan

Isoendoxan

Iso-endoxan

Iso-Endoxan

Isofosfamide

Isophosphamide

isosfamide

Isosfamide

LS-102

LS-99799

Mitoxana

Mitoxana, Ifex, Ifosfamide

MJF 9325

MJF-9325

MLS002154021

MolPort-003-666-704

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide

N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide

Naxamide

NCGC00016639-01

NCGC00179435-01

NCI60_000233

NCI-C01638

NPFAPI-04

NSC 109,724

NSC 109724

NSC109,724

NSC-109,724

NSC109724

NSC-109724

Prestwick0_000833

Prestwick1_000833

Prestwick2_000833

Prestwick3_000833

S1302_Selleck

SMR001233348

SPBio_002706

STL058690

UNII-UM20QQM95Y

WLN: T6NPOTJ AM2G BO B2G

Z 4942

Z4942

Z-4942

Etoposide

Approved

Phase 3

33419-42-0

36462

Synonyms:

(−)-etoposide

(-)-Etoposide

121471-01-0

136598-18-0

201594-04-9

33419-42-0

35317-32-9

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside

4-Demethylepipodophyllotoxin b-D-ethylideneglucoside

4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside

4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside

4-demethylepipodophyllotoxin β-D-ethylideneglucoside

4-Demethylepipodophyllotoxin β-D-ethylideneglucoside

4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside

4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin

51854-34-3

76576-58-4

9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

AB00438905

AC1L1FN8

AC1L1VT3

AC1L6246

AC1NR4OG

AC1O4WGG

AC1O7M1N

AC1Q47JJ

alpha-D-Glucopyranosyl isomer etoposide

Ambap33419-42-0

Baxter brand OF etoposide

Baxter oncology brand OF etoposide

Bio1_000489

Bio1_000978

Bio1_001467

BPBio1_000673

BRD-K37798499-001-02-5

Bristol myers brand OF etoposide

Bristol myers squibb brand OF etoposide

Bristol-myers brand OF etoposide

Bristol-myers squibb brand OF etoposide

BSPBio_000611

C01576

CCRIS 2392

Celltop

CHEBI:4911

CHEBI:588795

CHEMBL44657

CID11758093

CID284997

CID3310

CID36462

CID5284558

CID6419930

CID6610299

CPD000112002

D00125

DB00773

DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,

Demethyl epipodophyllotoxin ethylidine glucoside

Demethyl Epipodophyllotoxin Ethylidine Glucoside

Demethyl-epiodophyllotoxin ethylidene glucoside

Demethylepipodophyllotoxin-beta-D-ethylideneglucoside

E0675

E1383_SIGMA

EINECS 251-509-1

Epipodophyllotoxin VP-16213

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

Eposide

Eposin

Eposin, Vepesid, VP-16, Toposar, Etoposide

Eto gry

Eto-gry

Etomedac

ETOP

Etopol

Etopophos

Etopophos (phosphate salt)

Etopos

etoposide

Etoposide

Etoposide (JP15/USP/INN)

Etoposide (VP16)

Etoposide [USAN:INN:BAN:JAN]

Etoposide pierre fabre

Etoposide teva

Etoposide, (5a alpha)-isomer

Etoposide, (5a alpha,9 alpha)-isomer

Etoposide, (5S)-isomer

Etoposide, alpha D glucopyranosyl isomer

Etoposide, alpha-D-glucopyranosyl isomer

Etoposido

Etoposido [INN-Spanish]

Etoposido ferrer farma

Etoposidum

Etoposidum [INN-Latin]

Etosid

Exitop

Ferrer brand OF etoposide

Gry brand OF etoposide

HMS1569O13

HMS2052N05

HMS2089F14

HSDB 6517

I06-0248

KBioSS_002410

Lastet

Lemery brand OF etoposide

LS-1214

Medac brand OF etoposide

MLS000049957

MLS001074951

MLS001424283

MLS002153463

MLS002207239

MLS002222184

MolPort-003-983-431

MolPort-004-905-001

MolPort-004-955-161

NCGC00025056-02

NChemBio.2007.10-comp19

nchembio.573-comp8

nchembio873-comp2

NK 171

Novartis brand OF etoposide

NSC 141540

NSC141540

NSC-141540

Onkoposid

Onkoworks brand OF etoposide

Pharmachemie brand OF etoposide

Pierre fabre brand OF etoposide

Prasfarma brand OF etoposide

Prestwick_211

Prestwick0_000396

Prestwick1_000396

Prestwick2_000396

Prestwick3_000396

Riboposid

Ribosepharm brand OF etoposide

S1225_Selleck

SAM001246880

Sanfer brand OF etoposide

SMR000112002

SPBio_002532

ST056353

Tedec meiji brand OF etoposide

Teva brand OF etoposide

Teva, etoposide

Toposar

trans-Etoposide

UNII-6PLQ3CP4P3

Vepesid

VePesid

VePESID (TN)

Vepesid J

Vepeside

Vépéside sandoz

Vépéside-sandoz

VP 16

VP 16 (pharmaceutical)

VP 16213

VP 16-213

VP-16

VP-16-213

ZINC03830818

ZINC03938684

Zuyeyidal

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Synonyms:

(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide

11056-06-7

11116-31-7

1400-95-9

3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium

3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium

3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium

37208-04-1

37293-16-6

37353-43-8

9041-93-4

9041-93-4 (sulfate (salt))

AC1L9UFF

AC1NSEJD

AC1NUTOQ

Almirall brand OF bleomycin sulfate

Bellon brand OF bleomycin sulfate

Bellon, bléomycine

Blanoxan

Blenoxane

Bleo

Bleo cell

Bleo-cell

BLEOcell

Bleocin

Bleogin

Bleolem

Bleomicin

Bleomicina

Bleomicina [INN-Spanish]

bleomycin

Bleomycin

Bleomycin a(2)

Bleomycin A(2)

bleomycin a2

Bleomycin a2

Bleomycin A2

Bleomycin A2 & Bleomycin B2.

Bleomycin b(2)

Bleomycin B(2)

Bleomycin b2

Bleomycin B2

Bleomycin sulfate

Bleomycin sulphate

Bleomycine

Bleomycine [INN-French]

Bléomycine bellon

Bleomycins

Bleomycinum

Bleomycinum [INN-Latin]

Bleomycinum mack

BLM

Bristol myers squibb brand OF bleomycin sulfate

Bristol-myers squibb brand OF bleomycin sulfate

Bull brand OF bleomycin sulfate

C06854

C55H85N17O21S3

C55H86N17O21S3

CCRIS 2754

Cell pharm brand OF bleomycin sulfate

CHEBI:3139

CHEMBL403664

CID456190

CID5360373

CID5460769

DB00290

EINECS 234-356-5

HSDB 3208

Lemery brand OF bleomycin sulfate

LMPK14000006

LS-44860

LS-524

Lundbeck brand OF bleomycin sulfate

Mack brand OF bleomycin sulfate

Mack, bleomycinum

N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide

N1-(3-(Dimethylsulfonio)propyl)bleomycinamide

NDC 0015-3010

NSC 125066

Pingyangmyvin A2

STOCK1N-74760

Sulfate, bleomycin

UNII-13M89UEA7W

UNII-40S1VHN69B

Zhengguangmycin A2

Zhengguangmycin A2 [Chinese]

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

5310940 9887054 6857599 43805

Synonyms:

ACT 078

ACT-078

CHEMBL1201055

CID9887054

D01790

DACPLAT

Diaminocyclohexane Oxalatoplatinum

Eloxatin

Eloxatin (TN)

Eloxatine

Elplat

Foloxatine

L-OHP

L-OHP CPD

Oxalatoplatin

Oxalatoplatinum

oxaliplatin

Oxaliplatin

Oxaliplatin (JAN/USAN/INN)

Oxaliplatin [Usan:Inn:Ban]

oxaliplatine

oxaliplatino

Oxaliplatino [Spanish]

oxaliplatinum

Oxaliplatinum [Latin]

Oxaloplatine [French]

Oxaloplatino [Spanish]

Transplatin

Isophosphamide mustard

Phase 3

100427

Synonyms:

Ifosfamide mustard

Ifosforamide mustard

IPAM

Iphosphoramide mustard

Isophosphamide mustard

Isophosphoramide mustard

N,N'-di-(2-chloroethyl)phosphorodiamidic acid

NN'-Bis-(2-chloroethyl)phosphate

NN'-Bis-(2-chloroethyl)phosphoric acid

Palifosfamide

Palifosfamide-tris

Zio-201isophosphamide mustard

Alkylating Agents

Phase 3

Etoposide phosphate

Phase 3

Antimitotic Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Tubulin Modulators

Phase 3

Antibiotics, Antitubercular

Phase 3

Anti-Bacterial Agents

Phase 3

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Synonyms:

.Beta.,.beta.'-Dichlorodiethyl-N-methylamine

1, 5-Dichloro-3-methyl-3-azapentane hydrochloride

126-85-2 (N-oxide)

2,2'-Dichlorodiethyl-methylamine

2,2'-Dichloro-N-me

2,2'-dichloro-N-methyldiethylamine

2,2'-Dichloro-N-methyldiethylamine

2-Chloro-N-(2-chloroethyl)-N-methylethanamine

302-70-5 (N-oxide, hydrochloride)

51-75-2

55-86-7 (HYDROCHLORIDE)

AC1L1H9H

Antimit

b,Beta'-dichlorodiethyl-N-methylamine

beta,beta'-Dichlorodiethyl-N-methylamine

beta,Beta'-dichlorodiethyl-N-methylamine

bis(2-chloroethyl)methylamine

Bis(2-chloroethyl)methylamine

Bis(b-chloroethyl)methylamine

Bis(beta-chloroethyl) methylamine

Bis(beta-chloroethyl)methylamine

bis(β-chloroethyl)methylamine

Bis(β-chloroethyl)methylamine

BRN 0605323

BSPBio_001947

C07115

C5H11Cl2N

Carolysine

Caryolysin

Caryolysine

CCRIS 447

CHEBI:28925

CHEMBL427

Chloramine (the nitrogen mustard)

Chlorethazine

Chlormethine

Chlormethine (INN)

Chlormethine [INN:BAN]

Chlormethinum

Chlormethinum [INN-Latin]

CID4033

Cloramin

Clormetina

Clormetina [INN-Spanish]

D07671

DB00888

Di(2-chloroethyl)methylamine

Dichlor amine

Dichloren

DivK1c_000759

EINECS 200-120-5

Embechine

Embichin

ENT-25294

HMS1920J15

HMS2091B04

HMS502F21

HN2

HN-2

HSDB 5083

Hydrochloride N-oxide, mechlorethamine

Hydrochloride, mechlorethamine

I14-8708

IBS-L0033631

IDI1_000759

KBio1_000759

KBio2_001369

KBio2_003937

KBio2_006505

KBio3_001447

KBioGR_001448

KBioSS_001369

LS-7559

MBA

Me chloroethamine

Mebichloramine

mechlorethamine

Mechlorethamine

Mechlorethamine hydrochloride

Mechlorethamine hydrochloride N oxide

Mechlorethamine hydrochloride N-oxide

Mechlorethamine N oxide

Mechlorethamine N-oxide

Mechlorethamine oxide

Mechlorethanamine

Mechloroethamine

Mecloretamina

Mecloretamina [Italian]

Merck brand OF mechlorethamine hydrochloride

Merck frosst brand OF mechlorethamine hydrochloride

methylbis(2-chloroethyl)amine

Methylbis(2-chloroethyl)amine

Methylbis(b-chloroethyl)amine

Methylbis(beta-chloroethyl)amine

methylbis(β-chloroethyl)amine

Methylbis(β-chloroethyl)amine

Methylchlorethamine

Methyldi(2-chloroethyl)amine

Mitomen

Mitoxine (*Hydrochloride*)

MolPort-001-785-592

Mustargen

Mustine

Mustine note

Mutagen

N,N-Bis(2-chloroethyl)methylamine

N,N-Bis(2-chloroethyl)-N-methylamine

N,N-Di(chloroethyl)methylamine

NCGC00091835-02

NCGC00091835-03

NCGC00091835-04

NCGC00091835-05

NCI60_041682

NINDS_000759

Nitol (*Hydrochloride*)

Nitrogen mustard

Nitrogen mustard (HN-2)

Nitrogen mustard N oxide

Nitrogen mustard N-oxide

Nitrogranulogen

Nitromin

N-Lost

N-Methyl lost

N-Methyl-2,2'-dichlorodiethylamine

N-methyl-bis(2-chloroethyl)amine

N-Methyl-bis(2-chloroethyl)amine

N-Methyl-bis(b-chloroethyl)amine

N-Methyl-bis(beta-chloroethyl)amine

N-methyl-bis(β-chloroethyl)amine

N-Methyl-bis(β-chloroethyl)amine

N-Methyl-bis-chloraethylamin

N-Methyl-bis-chloraethylamin [German]

N-Methyl-lost

N-Methyl-lost [German]

N-Oxide, mechlorethamine hydrochloride

N-Oxide, nitrogen mustard

NSC 762

NSC762

NSC-762

SPBio_000496

Spectrum_000889

SPECTRUM1500375

Spectrum2_000448

Spectrum3_000484

Spectrum4_000924

Spectrum5_001702

Stickstofflost (*Hydrochloride*)

Stickstofflost (ebewe)

T 1024

T-1024

thyldiethylamine

TL 146

UNII-50D9XSG0VR

Β,beta'-dichlorodiethyl-N-methylamine

β,β'-dichlorodiethyl-N-methylamine

Anti-Infective Agents

Phase 2

Immunosuppressive Agents

Phase 2

Antiviral Agents

Phase 2

Antimetabolites

Phase 2

Immunologic Factors

Phase 2

Fluorodeoxyglucose F18

Radiopharmaceuticals

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT)	Active, not recruiting	NCT01726374	Phase 3	BEP(500)
2	A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors	Active, not recruiting	NCT00104676	Phase 3	cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
3	A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors	Unknown status	NCT02115165	Phase 2	Cabazitaxel
4	A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis	Unknown status	NCT00127049	Phase 2	gemcitabine, ifosfamide, cisplatin, G-CSF
5	A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy	Completed	NCT02317393	Phase 2
6	A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.	Completed	NCT02414685	Phase 2	Paclitaxel;Ifosfamide;Cisplatin
7	Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT)	Unknown status	NCT00553371
8	A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor	Completed	NCT00045045
9	Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor	Completed	NCT00003800

Search NIH Clinical Center for Nonseminomatous Germ Cell Tumor

Sources

Genetic Tests for Nonseminomatous Germ Cell Tumor

Sources

Anatomical Context for Nonseminomatous Germ Cell Tumor

MalaCards organs/tissues related to Nonseminomatous Germ Cell Tumor:

⁴⁰

Testis, Lymph Node, Pineal, Ovary, Bone Marrow, Testes, Thyroid

Sources

Publications for Nonseminomatous Germ Cell Tumor

Articles related to Nonseminomatous Germ Cell Tumor:

(show top 50) (show all 905)

#	Title	Authors	PMID	Year
1	Codon-specific translation reprogramming promotes resistance to targeted therapy. ⁶	Rapino F...Close P	29925953	2018
2	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. ⁶	Mass E...Geissmann F	28854169	2017
3	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. ⁶	Boussemart L...Vagner S	25079330	2014
4	Copper is required for oncogenic BRAF signalling and tumorigenesis. ⁶	Brady DC...Counter CM	24717435	2014
5	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. ⁶	Sun C...Bernards R	24670642	2014
6	Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. ⁶	Gala MK...Chung DC	24512911	2014
7	A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. ⁶	Kaplon J...Peeper DS	23685455	2013
8	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. ⁶	Das Thakur M...Stuart DD	23302800	2013
9	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. ⁶	Prahallad A...Bernards R	22281684	2012
10	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). ⁶	Poulikakos PI...Solit DB	22113612	2011
11	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. ⁶	Johannessen CM...Garraway LA	21107320	2010
12	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. ⁶	Nazarian R...Lo RS	21107323	2010
13	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. ⁶	Bollag G...Nolop K	20823850	2010
14	Inhibition of mutated, activated BRAF in metastatic melanoma. ⁶	Flaherty KT...Chapman PB	20818844	2010
15	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. ⁶	Pfister S...Lichter P	18398503	2008
16	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. ⁶	Lupi C...Basolo F	17785355	2007
17	BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. ⁶	Durante C...Russo D	17488796	2007
18	BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. ⁶	Liu D...Xing M	17374713	2007
19	Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. ⁶	Jo YS...Shong M	16772349	2006
20	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. ⁶	Xing M...Ladenson PW	16174717	2005
21	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. ⁶	Lubomierski N...Raedle J	16015629	2005
22	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. ⁶	Vasko V...Xing M	15998781	2005
23	High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. ⁶	Hishinuma A...Ieiri T	16187918	2005
24	Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. ⁶	Porra V...Rousset B	15687339	2005
25	Mutations of BRAF and RAS are rare events in germ cell tumours. ⁶	Sommerer F...Tannapfel A	15386408	2005
26	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. ⁶	Domingo E...Schwartz S	15342696	2004
27	Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. ⁶	Kumagai A...Yamashita S	15356022	2004
28	Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. ⁶	Xing M...Ladenson PW	15181070	2004
29	BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. ⁶	Puxeddu E...Santeusanio F	15126572	2004
30	BRAF T1796A transversion mutation in various thyroid neoplasms. ⁶	Xing M...Sidransky D	15001635	2004
31	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. ⁶	Kim IJ...Park JG	14513361	2003
32	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. ⁶	Nikiforova MN...Nikiforov YE	14602780	2003
33	Exclusion of BRAFV599E as a melanoma susceptibility mutation. ⁶	Meyer P...Garbe C	12794760	2003
34	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. ⁶	Kumar R...Hemminki K	12960123	2003
35	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. ⁶	Kimura ET...Fagin JA	12670889	2003
36	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. ⁶	Singer G...Shih IeM	12644542	2003
37	Absence of exon 15 BRAF germline mutations in familial melanoma. ⁶	Lang J...MacKie R	12619120	2003
38	High frequency of BRAF mutations in nevi. ⁶	Pollock PM...Meltzer PS	12447372	2003
39	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. ⁶	Rajagopalan H...Velculescu VE	12198537	2002
40	Mutations of the BRAF gene in human cancer. ⁶	Davies H...Futreal PA	12068308	2002
41	Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system? ⁶¹	Scandura G...Berney DM	33319858	2021
42	Pure testicular choriocarcinoma Cannonball metastases as a presenting imaging feature: A case report and a review of literature. ⁶¹	Aftan MK...Alzeena EFG	33613805	2021
43	[Diagnostic value of diffusion-weighted imaging and conventional magnetic resonance imaging in testicular tumor]. ⁶¹	Wang WW...Chen YQ	33685049	2021
44	Commentary: Predicting intrathoracic pathologic concordance in patients with metastatic nonseminomatous germ cell tumor is clearly unclear. ⁶¹	Boys J...Onaitis M	33451849	2021
45	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. ⁶¹	Donahoe LL...de Perrot M	33478834	2021
46	Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study. ⁶¹	Bhambhvani HP...Shah SA	33423934	2021
47	Primary mediastinal germ cell tumors - A retrospective analysis of >30 years of experience in a single institution. ⁶¹	Koizumi T...Takeda T	33502089	2021
48	Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. ⁶¹	Gerdtsson A...Kjellman A	33750683	2021
49	Could Aberrant Migration Explain Metachronous Germ Cell Tumors? ⁶¹	Kubicek P...Faure-Conter C	33017201	2021
50	Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. ⁶¹	Blok JM...Schaapveld M	33119475	2021

Sources

Genes for Nonseminomatous Germ Cell Tumor

Genes related to Nonseminomatous Germ Cell Tumor (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	400	Pathogenic ⁶	12960123 12068308 12447372 (more) 12619120 12794760 14513361 12198537 12644542 20818844 20823850 21107320 21107323 22113612 23302800 23685455 24670642 25079330 15342696 16015629 22281684 24512911 12670889 15001635 14602780 15356022 15126572 15181070 16174717 15687339 15998781 16187918 17374713 16772349 17488796 17785355 15386408 18398503 28854169 24717435 29925953
2	AFP	Alpha Fetoprotein	Protein Coding	7.43	GeneCards inferred via : Publications (show sections)
3	CGB5	Chorionic Gonadotropin Subunit Beta 5	Protein Coding	7.08	GeneCards inferred via : Publications (show sections)
4	CGB7	Chorionic Gonadotropin Subunit Beta 7	Protein Coding	7.08	GeneCards inferred via : Publications (show sections)
5	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.08	GeneCards inferred via : Publications (show sections)

Sources

Variations for Nonseminomatous Germ Cell Tumor

ClinVar genetic disease variations for Nonseminomatous Germ Cell Tumor:

⁶

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	BRAF	NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu)	SNV	Pathogenic	13961	rs113488022	GRCh37: 7:140453136-140453136 GRCh38: 7:140753336-140753336

Sources

Expression for Nonseminomatous Germ Cell Tumor

Search GEO for disease gene expression data for Nonseminomatous Germ Cell Tumor.

Sources

Pathways for Nonseminomatous Germ Cell Tumor

Pathways related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MAPK Pathway ⁶⁹ Show member pathways Toll-like Receptor Pathway ⁶⁹	11.25	ERBB2 BRAF
2	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁵ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁵ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁵ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁵ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁵ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁵ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁵	10.92	ERBB2 CGB5
3	Bladder cancer ³⁶ ¹	10.49	ERBB2 BRAF

Sources

GO Terms for Nonseminomatous Germ Cell Tumor

Biological processes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	9.46	ERBB2 CGB7 CGB5 BRAF
2	peptidyl-tyrosine phosphorylation	GO:0018108	9.26	ERBB2 BRAF
3	hormone-mediated signaling pathway	GO:0009755	8.96	CGB7 CGB5
4	female gamete generation	GO:0007292	8.62	CGB7 CGB5

Molecular functions related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein tyrosine kinase activity	GO:0004713	8.96	ERBB2 BRAF
2	hormone activity	GO:0005179	8.62	CGB7 CGB5

Sources

Sources for Nonseminomatous Germ Cell Tumor

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 20-May-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Nonseminomatous Germ Cell Tumor (NSGCT)

Aliases & Classifications for Nonseminomatous Germ Cell Tumor

MalaCards integrated aliases for Nonseminomatous Germ Cell Tumor:

Classifications:

External Ids:

Summaries for Nonseminomatous Germ Cell Tumor

Related Diseases for Nonseminomatous Germ Cell Tumor

Diseases related to Nonseminomatous Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Nonseminomatous Germ Cell Tumor:

Symptoms & Phenotypes for Nonseminomatous Germ Cell Tumor

GenomeRNAi Phenotypes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

Drugs & Therapeutics for Nonseminomatous Germ Cell Tumor

Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Nonseminomatous Germ Cell Tumor

Anatomical Context for Nonseminomatous Germ Cell Tumor

MalaCards organs/tissues related to Nonseminomatous Germ Cell Tumor:

Publications for Nonseminomatous Germ Cell Tumor

Articles related to Nonseminomatous Germ Cell Tumor:

Genes for Nonseminomatous Germ Cell Tumor

Genes related to Nonseminomatous Germ Cell Tumor (1 elite genes):

Variations for Nonseminomatous Germ Cell Tumor

ClinVar genetic disease variations for Nonseminomatous Germ Cell Tumor:

Expression for Nonseminomatous Germ Cell Tumor

Pathways for Nonseminomatous Germ Cell Tumor

Pathways related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

GO Terms for Nonseminomatous Germ Cell Tumor

Biological processes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

Molecular functions related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

Sources for Nonseminomatous Germ Cell Tumor